| Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant. |
businesswire.com |
2025-05-05 12:00:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma. |
businesswire.com |
2025-04-14 22:11:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML). |
businesswire.com |
2025-04-11 23:42:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Issuance of New Patent in Australia. |
businesswire.com |
2025-03-13 18:08:00 |
Czytaj oryginał (ang.) |
| CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc. |
businesswire.com |
2025-01-23 02:17:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc. |
businesswire.com |
2025-01-22 18:01:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Partners with GPCR Therapeutics Inc. to Fuel New Growth in Biotech. |
businesswire.com |
2024-12-26 22:08:00 |
Czytaj oryginał (ang.) |
| CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes. |
businesswire.com |
2024-12-21 15:48:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes. |
businesswire.com |
2024-12-20 18:42:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results. |
businesswire.com |
2024-11-14 18:01:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Receives Extension from Nasdaq Hearings Panel |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company's listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company is diligently working to timely satisfy the terms of the Panel's requests and to ensure. |
businesswire.com |
2024-09-18 20:01:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Announces 1-for-5 Reverse Stock Split |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure's common stock. |
businesswire.com |
2024-08-26 13:08:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics. |
businesswire.com |
2024-08-08 20:27:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Receives Positive Listing Determination from Nasdaq |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Receives Positive Listing Determination from Nasdaq. |
businesswire.com |
2024-08-01 20:01:00 |
Czytaj oryginał (ang.) |
| Why Is Exicure (XCUR) Stock Down 27% Today? |
Exicure (NASDAQ: XCUR ) stock is dropping on Monday after the prior early-stage pharmaceutical company's shares underwent a rally on Friday. That rally resulted in shares of XCUR stock rising 76% higher during normal trading hours. |
investorplace.com |
2024-07-22 12:37:30 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Reports First Quarter 2024 Financial Results |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. First Quarter 2024 Finan. |
businesswire.com |
2024-06-17 20:01:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Reports Full Year 2023 Financial Results |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2023 Financial Results. |
businesswire.com |
2024-06-06 20:01:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Received Nasdaq Notice of a Delisting Determination |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The Staff Delisting Determination notified the Company that since it has not yet filed its Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) per Nasdaq Listing Rule 5250(c)(1) (the “Rule”) by Nasdaq's extended d. |
businesswire.com |
2024-05-23 20:01:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Reports Third Quarter 2023 Financial Results |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Third Quarter 2023 Financial Results Ca. |
businesswire.com |
2024-05-16 20:08:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all. |
businesswire.com |
2024-04-22 20:01:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis. Under the terms of the agreement, Bluejay will receive an exclusive l. |
businesswire.com |
2024-02-05 18:01:00 |
Czytaj oryginał (ang.) |
| Why Is Exicure (XCUR) Stock Up 57% Today? |
Exicure (NASDAQ: XCUR ) stock is rising higher on Friday despite a lack of news from the early-stage biotechnology company. Exicure hasn't released any recent press releases or made any filings that would result in today's stock rally. |
investorplace.com |
2023-12-08 10:40:01 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies. |
businesswire.com |
2023-11-28 18:01:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors. |
businesswire.com |
2023-08-23 13:48:00 |
Czytaj oryginał (ang.) |
| Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update |
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update. |
businesswire.com |
2023-08-11 20:01:00 |
Czytaj oryginał (ang.) |
| 3 Nano-Cap Penny Stocks to Buy for Explosive Gains in 2023 |
Nano-cap penny stocks are arguably the most volatile and speculative investments you can make other than nano-cap cryptos. Shares of these small businesses generally have a market capitalization lower than $50 million. |
investorplace.com |
2023-04-14 11:01:45 |
Czytaj oryginał (ang.) |